We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Stock analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for shares of Rhythm Pharmaceuticals in ...

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Soleno Therapeutics (SLNO – Research Report) and ...

In this article, we are going to take a look at where Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) stands against other worst high-risk high-reward growth stocks to buy. On March 14, Tom Lee ...

Yann Mazabraud, the EVP of $RYTM, sold 55,803 shares of the company on 03-14-2025 for an estimated $2,886,226. We received data on the trade from a recent SEC filing ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

Detailed price information for Rhythm Pharmaceuticals Inc (RYTM-Q) from The Globe and Mail including charting and trades.

US biotech Rhythm Pharmaceuticals (Nasdaq: RYTM) has reacquired the rights to its obesity treatment Imcivree (setmelanotide) ...